Hemispherx Biopharma, Inc. Appoints Joseph Horvath as Deputy Chief Medical Officer
Hemispherx Biopharma, Inc. announced appointment of Joseph Horvath as deputy chief medical officer, to oversee Ampligen European pancreatic cancer programs. In this newly-created position, Dr. Horvath will assist the Company on various scientific aspects of development, manufacturing, regulatory, and medical affairs with a focus on assisting with the oversight of the current Ampligen Early Access Program (EAP) in place for pancreatic cancer. He served as Hemispherx' Director of R&D for seven years. He also served as Scientific Director of the Biotherapy Research Laboratories at St. Joseph Hospital's Cancer Institute in Tampa, FL.